Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% Receivables Turnover is 3.37 as of Mar. 2026. The stock has 1 warning sign investors should review. Among 202 Medical Diagnostics & Research companies, Invitro International ranks better than 90.59% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Invitro International's Revenue for the
three
months ended in Mar. 2026 was $0.21 Mil. Invitro International's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.06 Mil.
Hence, Invitro International's Receivables Turnover for the
three
months ended in Mar. 2026 was 3.37.
Invitro International (OTCPK:IVRO) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Invitro International Receivables Turnover Related Terms
Invitro International Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Invitro International's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVRO vs IDTA, PRPH, NSTM: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Invitro International's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Invitro International's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a Receivables Turnover of 3.37 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Invitro International and its competitors. According to the industry distribution chart, Invitro International ranks #19 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 9.4%.
Is Invitro International's Receivables Turnover too high?
Invitro International's current Receivables Turnover is 3.37. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Invitro International's value of 3.37 is 37.4% below this industry median. Based on the distribution chart, Invitro International ranks #19 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Invitro International's Receivables Turnover compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #19 out of 202 companies for Receivables Turnover. This places Invitro International in the top 9% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.38. Invitro International's value of 3.37 is 37.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current Receivables Turnover of 3.37 is 37.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current Receivables Turnover is 3.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current Receivables Turnover is 3.37 and 37.4% below the Medical Diagnostics & Research industry median of 5.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Invitro International (IVRO), the current Receivables Turnover is 3.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
